ChiCTR2100051569
结束
/
/
/
2021-09-27
/
/
新型冠状病毒肺炎(COVID-19)
Post COVID-19 pulmonary complications: a single center experience
Post COVID-19 pulmonary complications: a single center experience
46000
The current study aims to present a series of cases whom have developed short-term pulmonary complications after recovering from COVID-19.
连续入组
回顾性研究
No
N/A
Smart health tower
/
19
/
2021-01-05
2021-07-29
/
Those patients were included who were infected with SARS-CoV-2 and developed pulmonary symptoms in less than 6 months of recovery, or already had the symptoms during active infection but persisted even after recovery. These symptoms should be clearly related to COVID-19 infection.；
请登录查看Known cases of lung cancer, tuberculosis, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and other chronic lung diseases were excluded from the study.；
请登录查看Al-Jamhori teaching hospital
46000
Al-Jamhori teaching hospital的其他临床试验
伊拉克苏莱曼尼大学 Kscien Organization for Scientific Research的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04